Time To Scratch The "30-Year Itch" From MSCs' Questions

Following a 30-year latency pattern, we’d expect MSCs to boom in the 2020s after their initial characterization in the 1990s. We're exploring the questions behind why—after such compelling pre-clinical and human safety data—aren’t things progressing more quickly? Like other kinds of biotherapeutics, unexpected product development questions generate substantial perspiration to contend with many MSC therapeutics’ first inspirations.

These questions first stem from basic MSC biology—and how to best harness these cells’ innate strengths. This blog will attempt to briefly skim the surface of these perplexing questions, and how we might best answer them.